HUE034554T2 - Dikarbonsav vegyület - Google Patents

Dikarbonsav vegyület Download PDF

Info

Publication number
HUE034554T2
HUE034554T2 HUE14787530A HUE14787530A HUE034554T2 HU E034554 T2 HUE034554 T2 HU E034554T2 HU E14787530 A HUE14787530 A HU E14787530A HU E14787530 A HUE14787530 A HU E14787530A HU E034554 T2 HUE034554 T2 HU E034554T2
Authority
HU
Hungary
Prior art keywords
compound
group
ethyl
amino
benzoyl
Prior art date
Application number
HUE14787530A
Other languages
English (en)
Inventor
Yoshikazu Uto
Mikio Kato
Hidenori Takahashi
Yasuyuki Ogawa
Osamu Iwamoto
Hiroko Kono
Kazumasa Aoki
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of HUE034554T2 publication Critical patent/HUE034554T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (9)

  1. SZABADALMI H'.iÍ NYPONTOK Ç Αχ általános képleit? <1} vegyük:? vagy atmak gyogpxerésMtiífeg elfogadható sója vagy a vegyük? hidrán;» vagyonnak gyögysacACxodiog eübgadbaíó sói ív
    ÇÇ ahol xs)B',(kgyik sggpsp?ííptsnís m alábbiak «er??:? vs?). ileliniáha: R:‘; Cl·?'? aikil csoport, Cl-6 alkoxt €l~f> aikil csoport. C|-6: elktoalkO Söpört, '.agy 0-6 ctkíoalkd Cl-6 aikil csoport. Rv hidrogén atom vagy Mkrgén csoport. Rk hidrogén »?;>?». halogésr csoport, j?ak>geno Ol-h aikil csoport. hálogeno CI-0 alkoxs csopíXg C2~S telket? ciklikus- amino csoport. m~ül~§ slklatsifio esopssrt, €3-6 «kloaik;! €3-6 alkoss csoport. vagy Ol-Ö aiktjxi csoport. A: €3 h «ÂÉI gyűrik X: 03 vagy R RíOívagyR Z: €H vagy ki, es ív. egész. usnely ki va?; választva a ktAeíkgxok kd:4ik 3.2. 3.. és 4. 3:< Vcgyülot vagy mmk gyogpeesysxefiiag elfogadMârséia vagy a vegyüks hsi&amp;áp vagy at?nak :gyogyaastésatttíieg íjlksgaíiliatíl :só?s. as I. :igestypöt?i sxeriní, áix>l sx íliiaiéttos Mplet (i) szeri?)?; vegyülő? álMáíms képlet: (Π seeriaii ve??y«lot:
    m
  2. 3. A vegyölet: vagy a.?nmk gydgyKxergsxidlifeg dlbpáksíti soja vagy a; vggyület tssíkátja vagy an?«?k gy<3gysxe?ésgei:ilçg elsagiglljatö á?|ja,: ax I. vagy 2. Igó?)ypépt Siserini, abolit reproetnálja a következőket· n;cti! fispporR etil carport. tneíoxlstn csoport aklopropü csoport vagy cskloptopílfne-i! csopon.
  3. 4. A vegyük:·'· vagy atinak gyikgpgprésgeUlcg elíögadhíits sóik vagy a vegpiet huMpa vagy aanak gvogysrerMeitieg elfogadható söpg m í-3. igénypontok 'bármelyik® szeting ahol IC s'cptexsntaijs? ??. kove-kexöke?: hidrogén) alom, klór atom, vagy brota stot?).
  4. 5. A vegyüiöí vagy atmak gyógysxcrésxetníeg elfogadható sója vagy * vegyökg hkinPja vagy antta fe gyégysset'ésxetlieg eífegöíílhsto soi;g mí IA sgtoypiXipA bátssíosyike seome ahöí |v tegtezeníálía τ következőket hidrogén 4o=n. fluor ;Uotn. klór atom, Rom », iAfluormetli csoport. 2,2.· p!n’o8diî?-l ^î; csöpögj päpateuikv i - ü sAgaprb: ysppyrg PSk^tspite^oxt csoport vagy csoport. 6» A vegyük* vagy apaek clíogsJvöé s©|a vagy s, yegygfeí 1gpr*ja vagy arrnák a>|&amp;, P: rgssyporaok feto^ifc«. aM A dUëim&amp;t: %¥&amp;$&amp;$. reprc?:emák ?. A vogyüle; vagy agisák gyógya?eí«szeo!eg olfcgssiMó *ő.;a vagy a veyyükn Mrág* vagy asamk gyógysrctvsrcílicg djfogadhsaő sója. ac 1-6. %éa^e»ÂÂlÿiik« *&amp;Ä· K·· v · w; ?- «»»«»»k* Ol &amp; A veayületvagy anssk gydgyswïèszogipg ë fogadható sói* vagy a. vagy«*«* iáőtbpa: vagy amas '.g^Âî't'v'vnhe > C'Av*‘hak Mja a-» " .gCTvpt»'«'! -wtnuKrkc* a.'i <1 o. *> •Sk .^.Λ^>#l¾î·Wf>^··«íW¾k:Jyé¾ÿ^^2<'t,le¾ "kc-gíitíhasó sósa vág> * ytgv<jk'- Λ '*-'' "··'*** gyégy^erésrcdicg elfogaÄfo sója, S? 1- vagy 2. igénypont sxsrM a*»>» mpMgy^ ^Manur-a- * kbvakezo swW-tituen* csoporíyk bármelyik«: py Sien! csoport c;ól csoport, ;s«?oxk*ü csoport ciklopropH csoport. &amp;&amp; oklopropiimeti? csoport R-: hàbogenatem, klórafors, *%&amp;»*»«* „í ,, , %,iw ßooraiom, Ifciii* mifoort»«*« os^g R/itkumgarvaîOïïy isuv. va.vst; _ ^t^mOnBíeiáés . . . !:!!,»K J-" ' Í '«cpo't diets bits» 5v .-"'£'<-5 csoport pim-slidství- i· c^opvo.. pga-mo,. > t TOCKíXi OXOpüCk ..4: iîiklebxàagy X:CH éyM, V : CH és X, Z: CH és N, és
    foZMfo ( v»|;vg a kőveMrökboi álló
  5. 10, Az I, ,,*«.«* —“ *®íite’ *” * ””"** * ' ' ' csoportból:
    vagy aasüík gvógyssxerésa^sieg elibgadhak sósa vagy a vegytkî Mdrátjs vágy ásásuk gyógysserésKetlJóg síi fogadkak sója.
  6. 11 , Az 1. Igssiypoas: saemsó vsgydktstel s vegyidet a kővetkező képlet sa<ki;t;i:
    vagy mmk: gyógysseísüzetileg sdtógadltaíé sója vagy a vegyük; kovát;« vagy amsak gyógyszííííkssefiieg elfogadható sója,
  7. 12. Az I. igé«y|v>«t seetésti vegyuleí, atei a vegyidet a töve&amp;s&amp;ó képlet sskfigd::
    vagy aesiak gyógySzeíészéóteg gjfepdkaíó sója vagy a vegyük; hidíáíja vagy a sasuk Iyógyszerészetlieg ekygadkvó sója. 13. A;·: 1. igestypegt a/csasii vegytlkt, sise! a vegyidet a kowskezé képlet saedmí:
    vagy asmsk gyógyazéiészstdeg elfogadhsk sója vagy a vegyük; kkkátja vagy aswssk gyógyszérészéídég eisőgádhaié sója.
  8. 14, Aj. ). igénypont *ícnm; vegyük*. ahol a vegyukn a következő kép!« :
    ^gy Atmak vy^gyszcreazetslcg:' ^fogadható sója vagy a vegplei I§áp: vagy: inmi± : dlbpdMiÖ SíSjp: L5. A (0-54 igcry.poÍíiok UheveUokv sseràô gyögysaeKv.zeOäeg elfogadható so, amely dikaLuiíy !jó 16, A. ssadgd -S<*> 4Spy áigígmgs p. 17, >1 ; 5, vágy ! fiigásypPt sgörinfi gpgpzeréivKpfeg$fciga#a|# só, ppy amtákihp-áfjs, W> A vppip vagy amsak ipgpge^szeiilsg: elfogadható : séja,: vagy a vsgpfot hkhpp vágy .$aaák: ,p5l»f:É«Íl^ áifopdható söp,m 1-17, igéöyipííí^lJáösslyiké «!»> íétUmmmmmüfimm·.. JÄ. Cíyögpmfesii fempPdö, amely isíPlmássaa m M'7- ktealylte·. umná'. vpyideiet vagy ::tmnú ' -g^^^sréssdÉeg dibpdhsfo sép:, vagy &amp;, vegyül« híMtját vagy wä
  9. 70. A W, igégypat szerinh pogysadpáp korapotóckx Mh&amp;pipá«» hiperfö^huámia megelőzésbe vagy kezelésére. 7-1. A vegyük* vagy aunak gyö^zer&amp;wnfcg elfogadható Pp vagy a vegyük* hidrába vagy armak gpgysüerssxefíkíg elfogadbstó söp, m 1-17* igPyisoRtok bai^íielyskp sKgritp IMIlPPspsm hïp«PssaÊitémia mege!&amp;«s6iv vapy telMs-e.
HUE14787530A 2013-04-24 2014-04-23 Dikarbonsav vegyület HUE034554T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013091090 2013-04-24

Publications (1)

Publication Number Publication Date
HUE034554T2 true HUE034554T2 (hu) 2018-02-28

Family

ID=51791887

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14787530A HUE034554T2 (hu) 2013-04-24 2014-04-23 Dikarbonsav vegyület

Country Status (28)

Country Link
US (2) US9617232B2 (hu)
EP (1) EP2990400B1 (hu)
JP (1) JP5774253B2 (hu)
KR (1) KR102168259B1 (hu)
CN (3) CN105121405A (hu)
AU (1) AU2014258419B2 (hu)
BR (1) BR112015026840A2 (hu)
CA (1) CA2909400C (hu)
CY (1) CY1119296T1 (hu)
DK (1) DK2990400T3 (hu)
ES (1) ES2640802T3 (hu)
HK (1) HK1222385A1 (hu)
HR (1) HRP20171273T1 (hu)
HU (1) HUE034554T2 (hu)
IL (1) IL242195B (hu)
LT (1) LT2990400T (hu)
MX (1) MX2015014921A (hu)
MY (1) MY170262A (hu)
NZ (1) NZ712660A (hu)
PH (1) PH12015502429B1 (hu)
PL (1) PL2990400T3 (hu)
PT (1) PT2990400T (hu)
RS (1) RS56243B1 (hu)
RU (1) RU2662817C2 (hu)
SG (1) SG11201508542SA (hu)
SI (1) SI2990400T1 (hu)
TW (1) TWI594975B (hu)
WO (1) WO2014175317A1 (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI594975B (zh) * 2013-04-24 2017-08-11 第一三共股份有限公司 二羧酸化合物
EP3199529B1 (en) * 2014-09-26 2021-01-27 Daiichi Sankyo Company, Limited Salt of dicarboxylic acid compound
TW201700458A (zh) * 2015-04-24 2017-01-01 第一三共股份有限公司 二羧酸化合物之製法
JP2019533022A (ja) 2016-10-24 2019-11-14 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
SG11202009280RA (en) * 2018-03-23 2020-10-29 Yumanity Therapeutics Inc Compounds and uses thereof
WO2023219127A1 (ja) * 2022-05-11 2023-11-16 中外製薬株式会社 嚢胞性疾患を治療または予防するための医薬組成物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK656789A (da) 1988-12-28 1990-06-29 Takeda Chemical Industries Ltd Benzoheterocykliske forbindelser
DD280329A1 (de) * 1989-03-09 1990-07-04 Bitterfeld Chemie Dispersionsfarbstoffpraeparate zum faerben und bedrucken von polyestermaterialien i
TW575563B (en) 1997-08-19 2004-02-11 American Cyanamid Co Process for the preparation of pyridyl carboxylic amides and esters
JPWO2003048134A1 (ja) * 2001-12-05 2005-04-14 日本たばこ産業株式会社 トリアゾール化合物及びその医薬用途
US20040142981A1 (en) * 2002-08-23 2004-07-22 Atli Thorarensen Antibacterial benzoic acid derivatives
EP1614676A4 (en) * 2003-03-27 2009-03-25 Kirin Pharma Kk PHOSPHORUS TRANSPORT IN VIVO INHIBITOR COMPOUND AND MEDICAMENT CONTAINING THE SAME
FR2872159B1 (fr) 2004-06-28 2007-10-05 Merck Sante Soc Par Actions Si Nouveaux derives acides carboxyliques phenyliques et leur utilisation dans le traitement du diabete
KR20110027657A (ko) * 2008-06-25 2011-03-16 다이이찌 산쿄 가부시키가이샤 카르복실산 화합물
SG175253A1 (en) 2009-05-26 2011-11-28 Abbott Lab Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
DE102009046115A1 (de) * 2009-10-28 2011-09-08 Bayer Schering Pharma Aktiengesellschaft Substituierte 3-Phenylpropansäuren und ihre Verwendung
SG184497A1 (en) 2010-04-12 2012-11-29 Somalogic Inc 5-position modified pyrimidines and their use
AU2011246072B2 (en) * 2010-04-28 2014-06-26 Astellas Pharma Inc. Tetrahydrobenzothiophene compound
WO2012054110A2 (en) * 2010-07-07 2012-04-26 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
BR112014010169B1 (pt) * 2011-10-27 2021-12-07 Astellas Pharma Inc Compostos de derivado n-tienilbenzamida substituída com aminoalquil, composição contendo os ditos compostos e uso dos mesmos para prevenir ou tratar hiperfosfatemia
WO2013082751A1 (en) * 2011-12-06 2013-06-13 Leo Pharma A/S Phosphate transport inhibitors i
WO2013082756A1 (en) * 2011-12-06 2013-06-13 Leo Pharma A/S Phosphate transport inhibitors ii
WO2014003153A1 (ja) 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
TWI594975B (zh) * 2013-04-24 2017-08-11 第一三共股份有限公司 二羧酸化合物
EP3199529B1 (en) * 2014-09-26 2021-01-27 Daiichi Sankyo Company, Limited Salt of dicarboxylic acid compound

Also Published As

Publication number Publication date
RS56243B1 (sr) 2017-11-30
TW201500338A (zh) 2015-01-01
WO2014175317A1 (ja) 2014-10-30
RU2015150120A (ru) 2017-05-29
ES2640802T3 (es) 2017-11-06
KR20160002743A (ko) 2016-01-08
EP2990400B1 (en) 2017-06-21
CN107311895A (zh) 2017-11-03
LT2990400T (lt) 2017-09-11
PT2990400T (pt) 2017-09-25
NZ712660A (en) 2019-10-25
TWI594975B (zh) 2017-08-11
HRP20171273T1 (hr) 2017-10-20
EP2990400A1 (en) 2016-03-02
AU2014258419B2 (en) 2018-08-09
US9617232B2 (en) 2017-04-11
BR112015026840A2 (pt) 2017-07-25
RU2662817C2 (ru) 2018-07-31
DK2990400T3 (da) 2017-10-09
IL242195B (en) 2019-08-29
CN107337621A (zh) 2017-11-10
AU2014258419A2 (en) 2015-11-19
SI2990400T1 (sl) 2017-08-31
US20160046568A1 (en) 2016-02-18
AU2014258419A1 (en) 2015-10-22
CN105121405A (zh) 2015-12-02
US20170015641A1 (en) 2017-01-19
CA2909400C (en) 2017-06-27
JPWO2014175317A1 (ja) 2017-02-23
MX2015014921A (es) 2016-06-02
EP2990400A4 (en) 2016-10-19
CA2909400A1 (en) 2014-10-30
MY170262A (en) 2019-07-15
US9670173B2 (en) 2017-06-06
PH12015502429A1 (en) 2016-02-22
CY1119296T1 (el) 2018-02-14
HK1222385A1 (zh) 2017-06-30
PH12015502429B1 (en) 2016-02-22
PL2990400T3 (pl) 2017-10-31
SG11201508542SA (en) 2015-11-27
JP5774253B2 (ja) 2015-09-09
KR102168259B1 (ko) 2020-10-21

Similar Documents

Publication Publication Date Title
HUE034554T2 (hu) Dikarbonsav vegyület
JP5897566B2 (ja) 環式ｎ，ｎ’−ジアリールチオ尿素及びｎ，ｎ’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用
JP2017128605A (ja) 抗ウイルス化合物の固体形態
US6242460B1 (en) Zolpidem salt forms
JP6581193B2 (ja) 置換２−チオキソ−イミダゾリジン−４−オン及びそのスピロ類似体、抗癌有効成分、医薬組成物、医薬製剤、並びに前立腺癌の治療法
TWI694069B (zh) 治療精神分裂症之醫藥調配物
TW201516042A (zh) 組織胺ｈ受體之苯并咪唑－２－基嘧啶調控劑
WO2015108038A1 (ja) エチレングリコール化合物
JP2015199763A (ja) トランスノルセルトラリンの製剤、塩、及び多形体、並びにその使用
KR20230162935A (ko) 포유류 slc6a19 기능의 소형 분자 저해제
US20230382870A1 (en) N-aromatic amide compounds, preparation methods and uses thereof
WO2015064532A1 (ja) モルホリン化合物
EP3199529B1 (en) Salt of dicarboxylic acid compound
TW201141861A (en) [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1H-pyrrolo-pyridin-yl)-methanones and synthesis thereof
CN114456150A (zh) Nr2b受体拮抗剂或其可药用的盐、制备方法及用途
TW202012362A (zh) 稠合三環γ-胺基酸衍生物之組合物及其製備方法